Youdim Kuresh A, Lyons Richard, Payne Leon, Jones Barry C, Saunders Kenneth
Pfizer Global Research and Development, Pharmacokinetics Dynamic and Metabolism, Sandwich, Kent, UK CT13 9NJ, United Kingdom.
J Pharm Biomed Anal. 2008 Sep 10;48(1):92-9. doi: 10.1016/j.jpba.2008.05.011. Epub 2008 May 17.
The current study focused on the development of an automated IC50 cocktail assay in a miniaturized 384 well assay format. This was developed in combination with a significantly shorter high pressure liquid chromatography (HPLC) separation and liquid chromatography-mass spectrometry (LC-MS/MS) run-time; than those currently reported in the literature. The 384-well assay used human liver microsomes in conjunction with a cocktail of probe substrates metabolized by the five major CYPs (tacrine for CYP1A2, diclofenac for CYP2C9, (S)-mephenytoin for CYP2C19, dextromethorphan for CYP2D6 and midazolam for CYP3A4). To validate the usefulness of the automated and analytical methodologies, IC50 determinations were performed for a series of test compounds known to exhibit inhibition across these five major P450s. Eight compounds (sertraline, disulfuram, ticlopidine fluconazole, fluvoxamine, ketoconazole, miconazole, paroxetine, flunitrazepam) were studied as part of a cocktail assay, and against each CYPs individually. The data showed that the IC50s generated with cocktail incubations did not differ to a great extent from those obtained in the single probe experiments and hence unlikely to significantly influence the predicted clinical DDI risk. In addition the present method offered a significant advantage over some of the existing cocktail analytical methodology in that separation can be achieved with run times as short as 1 min without compromising data integrity. Although numerous studies have been reported to measure CYP inhibition in a cocktail format the need to support growing discovery libraries not only relies on higher throughput assays but quicker analytical run times. The current study reports a miniaturized high-throughput cocktail IC50 assay, in conjunction with a robust, rapid resolution LC-MS/MS end-point offered increased sample throughput without compromising analytical sensitivity or analyte resolution.
当前的研究聚焦于在小型化的384孔分析形式中开发一种自动化的IC50鸡尾酒分析法。它是与明显更短的高压液相色谱(HPLC)分离和液相色谱 - 质谱联用(LC-MS/MS)运行时间相结合开发的;比目前文献中报道的时间更短。这种384孔分析法使用人肝微粒体以及由五种主要细胞色素P450(CYP)代谢的探针底物混合物(CYP1A2的他克林、CYP2C9的双氯芬酸、CYP2C19的(S)-美芬妥因、CYP2D6的右美沙芬和CYP3A4的咪达唑仑)。为了验证自动化和分析方法的实用性,对一系列已知在这五种主要细胞色素P450中表现出抑制作用的测试化合物进行了IC50测定。作为鸡尾酒分析法的一部分,研究了八种化合物(舍曲林、双硫仑、噻氯匹定、氟康唑、氟伏沙明、酮康唑、咪康唑、帕罗西汀、氟硝西泮),并分别针对每种细胞色素P450进行研究。数据表明,鸡尾酒孵育产生的IC50与单探针实验中获得的IC50在很大程度上没有差异,因此不太可能显著影响预测的临床药物相互作用风险。此外,本方法相对于一些现有的鸡尾酒分析方法具有显著优势,因为可以在仅1分钟的运行时间内实现分离,而不影响数据完整性。尽管已经有许多研究报道了以鸡尾酒形式测量细胞色素P450抑制作用,但支持不断增长的发现文库的需求不仅依赖于更高通量的分析方法,还依赖于更快的分析运行时间。当前的研究报告了一种小型化的高通量鸡尾酒IC50分析法,结合强大、快速分离的LC-MS/MS终点检测,在不影响分析灵敏度或分析物分辨率的情况下提高了样品通量。